Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 9

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 9
---
 “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements
are based upon management’s assumptions, expectations, projections, intentions and beliefs about future events. Except for historical
information, the use of predictive, future-tense or forward-looking words such as “intend,” “plan,” “predict,”
“may,” “will,” “project,” “target,” “strategy,” “estimate,” “anticipate,”
“believe,” “expect,” “continue,” “potential,” “forecast,” “should”
and similar expressions, whether in the negative or affirmative, that reflect our current views with respect to future events and operational,
economic and financial performance are intended to identify such forward-looking statements. Such forward-looking statements are only
predictions, and actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking
statements as a result of risks and uncertainties, including, without limitation, the Company’s ability to execute on its business
strategy, including its plans to develop and commercialize its product candidates; the Company’s ability to comply with obligations
as a public reporting company; the Company’s ability to maintain compliance with the listing standards of The Nasdaq Stock Market
(“Nasdaq”); the ability of the Company to timely and effectively implement controls and procedures required by Section 404
of the Sarbanes-Oxley Act of 2002; risks resulting from the Company’s status as an emerging growth company, including that reduced
disclosure requirements may make shares of our common stock, par value $0.0001 per share (the “Common Stock”), less attractive
to investors; the Company’s ability to continue as a going concern; risks related to Petros’ history of incurring significant
losses; risks related to the Company’s ability to obtain regulatory approvals for, or market acceptance of, any of its products
or product candidates; and the impact of the public health emergencies, and the related responses of governments, consumers, customers,
suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations. Additional
factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are described
in the Company’s quarterly reports on Form 10-Q, in “Risk Factor Summary” and in Part I, Item 1A., “Risk
Factors,” in the Company’s Annual